The Department of Infection, Immunity and Cardiovascular Disease was formed in September 2015 following the merger of the former Departments of Cardiovascular Science and Infection and Immunity bringing together research strengths in inflammation, infection, medical and biomedical imaging, discovery science using experimental model systems and cardiopulmonary medicine in particular. This exciting new development arose in part from the Tooke Review of Biomedical Life Sciences carried out by Sir John Tooke in 2014.
Building and Facilities
The Department has a large footprint occupying 4 research floors in the Royal Hallamshire Hospital in a prime position for translation of discoveries to man. In addition, our academic medical imaging unit is based on C floor adjacent to the main NHS Radiology Department. A brand new development, MRC POLARIS at 20 Claremont Crescent opened in January 2016. Some researchers also share labs in Firth Court area near the aquaria and others undertaking clinical trials research in Cardiology are based at the Clinical Research Facility, Northern General Hospital.
Our laboratories house state-of-the-art facilities including cell biology, genomics, clinical research facilities, skin barrier laboratories, medical imaging, vertebrate and mammalian models and containment 2 and 3 facilities for pathogens.
The Department fulfils an important research-led role teaching on the Sheffield MBChB course covering important parts of the course e.g. Infections, Cardiology, Nephrology, Radiology and Respiratory medicine. In addition, we lead a very successful postgraduate programme in Molecular Medicine with several specialist pathways. We teach undergraduate medical physics modules and undergraduate pharmacology modules within the Faculty of Science.
Our research broadly seeks to understand mechanisms of inflammation in the context of lung, heart and, more recently, brain disease. Our research encompasses a global priority, Infectious Disease, in which we seek to understand the interactions between infective bacteria and the immune system.
Sheffield also hosts the largest European centre for pulmonary vascular disease; and we have developed novel methods of medical imaging and modelling, which are leading to new and better treatment decisions for patients. Our Department has pioneered the use of in silico modelling in decision-making at the time of percutaneous coronary intervention, and is at the forefront of anti-platelet strategies in acute coronary syndromes.